CYCC

Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022

Retrieved on: 
Thursday, January 6, 2022
Lymphoma, Safety, COVID-19, Review, Research, Company, Patient, Lead Candidate, IND, PLK1, All rights reserved, Lymphatic system, Cell cycle, CYCC, Cyclacel, Annual report, NASDAQ, FDA, Hematology, News, GLOBE, Risk, Pharmaceutical industry, Fine chemical

BERKELEY HEIGHTS, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2021 achievements and outlining the Company’s key business objectives for 2022.

Key Points: 
  • This past year proved to be very productive for Cyclacel as we achieved our planned business objectives, said Spiro Rombotis, President and Chief Executive Officer.
  • First and foremost, we initiated two registration-directed, Phase 1/2 trials for our lead candidate fadraciclib, an oral CDK2/9 inhibitor.
  • Copyright 2022 Cyclacel Pharmaceuticals, Inc. All Rights Reserved.
  • The Cyclacel logo and Cyclacel are trademarks of Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 10, 2021
Hematology, Safety, Cancer, Lymphatic system, News, All rights reserved, Clinical trial, R, ET, Security (finance), NASDAQ, Leukemia, Research, FDA, Annual report, Conference, Company, U.S. Securities and Exchange Commission, GLOBE, Conference call, PLK1, CYCC, Cell cycle, Patient, Risk, IND, Fine chemical, Pharmaceutical industry, Medical imaging

BERKELEY HEIGHTS, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the third quarter 2021. The quarter’s business highlights include an update on the Company’s progress with fadraciclib and CYC140, Cyclacel's novel CDK2/9 and PLK1 inhibitors, respectively.

Key Points: 
  • ET -
    BERKELEY HEIGHTS, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the third quarter 2021.
  • The quarters business highlights include an update on the Companys progress with fadraciclib and CYC140, Cyclacel's novel CDK2/9 and PLK1 inhibitors, respectively.
  • Copyright 2021 Cyclacel Pharmaceuticals, Inc. All Rights Reserved.
  • The Cyclacel logo and Cyclacel are trademarks of Cyclacel.

Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update

Retrieved on: 
Friday, October 29, 2021
Safety, Research, CYCC, Security (finance), U.S. Securities and Exchange Commission, Patient, NASDAQ, Hematology, Risk, Lymphatic system, PLK1, Annual report, Cell cycle, Company, All rights reserved, News, GLOBE, Fine chemical, Pharmaceutical industry

BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.(NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results and provide a business update onWednesday, November 10, 2021.

Key Points: 
  • BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.(NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results and provide a business update onWednesday, November 10, 2021.
  • Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology.
  • This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.
  • The Cyclacel logo and Cyclacel are trademarks of Cyclacel.

Cyclacel Pharmaceuticals Presenting at Three Conferences in September

Retrieved on: 
Wednesday, September 8, 2021

BERKELEY HEIGHTS, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in three investor conferences in September.

Key Points: 
  • BERKELEY HEIGHTS, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in three investor conferences in September.
  • Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology.
  • Copyright 2021 Cyclacel Pharmaceuticals, Inc. All Rights Reserved.
  • The Cyclacel logo and Cyclacel are trademarks of Cyclacel.

Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 11, 2021
Cholangiocarcinoma, Conference call, PLK1, Risk, NASDAQ, Patient, MYC, Biomarker, Annual report, R, FDA, Conference, File, Simon, Company, Lymphoma, ET, Lymphatic system, Cyclin E, GLOBE, Research, Hematology, Security (finance), Breast, Leukemia, Safety, News, CDK, U.S. Securities and Exchange Commission, CYCC, KRAS, Cancer, IND, Histology, Cell cycle, Clinical trial, All rights reserved, Fine chemical, Pharmaceutical industry

BERKELEY HEIGHTS, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the second quarter 2021. The quarter’s business highlights included an update on the Company’s progress with fadraciclib and CYC140, Cyclacel's novel CDK2/9 and PLK1 inhibitors, respectively.

Key Points: 
  • ET -
    BERKELEY HEIGHTS, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the second quarter 2021.
  • The quarters business highlights included an update on the Companys progress with fadraciclib and CYC140, Cyclacel's novel CDK2/9 and PLK1 inhibitors, respectively.
  • The Company expects to begin a study in patients with solid tumors in the second half of 2021.
  • The Cyclacel logo and Cyclacel are trademarks of Cyclacel.